The opioid epidemic: how centuries of painkiller use sparked a public health crisis

Opioid overdose killed 80,411 Americans in 2021, making up most fatal overdoses that year and putting the United States at the center of the world’s opioid crisis.
Back in the Victorian era, doctors handed out opium tinctures for everything, even for fussy teething infants, while field surgeons during the Civil War turned to morphine for wounded soldiers. Fast forward to the 20th century – codeine for coughs, oxycodone for chronic pain – each new drug strengthened the belief that pain was something to be medicated, not endured.

By the late 1900s, pharmaceutical companies rebranded pain relief as not just a medical goal but a basic right. Regulators didn’t keep pace with this cultural shift. Americans quickly absorbed the new logic: discomfort meant a prescription, and opioids, once reserved for the dying, moved into everyday use.
Decades of normalized opioid use quietly set the trap for a public health emergency.

What is the opioid epidemic and how is it defined?

In 2017, the Centers for Disease Control and Prevention (CDC) labeled the shocking rise in overdose deaths – from both prescription opioids like oxycodone and illicit drugs like heroin – a national emergency. The phrase opioid epidemic captures how opioid-related illness and death kept climbing, starting with pain treatment and ending with widespread opioid use disorder (OUD), then fatal overdoses.

The CDC tracks opioid overdose deaths using ICD-10 codes – counting any death where opioids, whatever the source, were the root cause. OUD sits at the center of this crisis: a chronic, relapsing disorder marked by compulsive drug use despite harm. The result: individual suffering ripples into a collapse of entire systems.
Here, addiction collides with public health breakdowns and slow regulatory response.

A single overdose can set off a cascade of medical, social, and economic consequences.

A historical timeline of the opioid crisis

When Purdue Pharma launched OxyContin in 1995, the company marketed it as a breakthrough, claiming lower addiction risk than older opioids. Within months, attitudes in pain management shifted – the American Pain Society in 1996 unveiled “pain as the 5th vital sign,” telling doctors to check pain as routinely as blood pressure.

This new priority became official when the Joint Commission folded pain standards into its 2001 hospital accreditation process. By 2000, the Drug Addiction Treatment Act allowed doctors to prescribe some opioid addiction treatments, and the FDA cleared buprenorphine (Subutex, Suboxone) in 2002 – formally recognizing opioid dependence as treatable.

That same decade, pain joined the vital signs – and opioid dependence became just another treatable disease.

Purdue’s relentless marketing, together with new guidelines and mandates, triggered a spike in opioid prescriptions through the late 1990s and early 2000s.
Providers, squeezed by accreditation rules and patient satisfaction scores, prescribed opioids as the go-to for pain – often with little evidence on long-term safety.

Pain, once an invisible symptom, became a clinical metric, and pharmaceutical innovation blurred the line between relief and risk.

The three waves of the opioid epidemic

In the late 1990s, doctors across the United States increasingly prescribed opioids like hydrocodone, oxycodone, and hydromorphone-marking the first wave of the opioid crisis. The National Institute on Drug Abuse (NIDA) tracked the trend: prescription opioid sales quadrupled from 1999 to 2010, and overdose deaths rose in step.

In 2010, new regulations slowed prescription access but opened the door to heroin, which was cheaper and easier to get – kicking off the second wave. Heroin-related deaths tripled between 2010 and 2014, overwhelming public health. A third wave hit in 2013 when illicit fentanyl – made in underground labs, up to 100 times stronger than morphine – flooded the market and sent overdose deaths skyrocketing in cities and rural areas alike.

Cutting off painkillers sent people to heroin, then fentanyl, with deadly results.

NIDA’s research showed these waves overlapped, each making it harder to fight the epidemic and raising the risk for those caught in the middle.

This crisis is not a single surge, but a sequence of shifting threats-each more destabilizing than the last.

How the crisis evolved from prescription painkillers to heroin and fentanyl?

As prescription painkillers dried up, laid-off workers in Appalachia and closed factories in the Midwest left whole towns vulnerable to cheap, potent street heroin. Mexico flooded the market with purer heroin at lower prices, while Chinese-made precursors powered fentanyl production just over the border.
As pill formulas changed and monitoring tightened, oxycodone use declined, driving more people toward heroin, which became easier to obtain than regulated pain medicine.

Teams from the National Institutes of Health HEAL Initiative documented the fallout: heroin overdose deaths jumped fourfold from 2010 to 2015, and then synthetic fentanyl quickly outpaced heroin as the top killer. Methadone clinics tried to slow the deaths, but rural areas – because of distance, stigma, and shortages of doctors – kept seeing higher mortality rates.

Tamper-proof pills drove people to heroin and fentanyl, and the death toll only climbed.

Fentanyl now dominates the deadliest phase of America’s crisis. Trafficked from Mexico and lethal in microgram doses, it’s changed the landscape entirely.

Root causes: overprescription and regulatory failures

Regulatory failures by the US Food and Drug Administration (FDA) paired with aggressive drug marketing fueled an unprecedented rise in opioid prescribing after 1995. The FDA approved OxyContin without strong long-term addiction data, while marketing campaigns sold pain relief as a right. Hospital leaders, influenced by the “Pain as the Fifth Vital Sign” push, required pain assessments every visit and nudged clinicians toward opioids even for moderate complaints.

From 1996 to 2010, opioid prescriptions surged-quadrupling nationwide as use for non-cancer pain became routine.

The President’s Commission on Combatting Drug Addiction and the Opioid Crisis found in 2017 that weak oversight – everything from FDA approval to enforcement – led to mass overprescribing. The National Academies’ 2017 report pinned the crisis on failures in regulation, marketing, and changing clinical culture. Even after prescriptions plateaued, stigma, barriers to care, and genetic risk continued to drive the epidemic.

Pharmaceutical lobbying, inadequate monitoring systems, and a cultural shift toward medicating discomfort entrenched a cycle of dependence and harm.

Measuring and tracking the opioid epidemic today

In Atlanta, CDC epidemiologists track opioid deaths by parsing coroner reports, toxicology results, and prescription registries almost in real time. Their algorithms detect spikes in overdose deaths – especially those tied to fentanyl or newborn withdrawal – across counties from West Virginia to New Mexico.

The CDC Guideline for Prescribing Opioids for Chronic Pain, in place since 2016, is now the backbone of national surveillance – standardizing how data on prescriptions and side effects is gathered. The Substance Abuse and Mental Health Services Administration (SAMHSA) pulls together treatment admissions, tracking opioid program coverage and naloxone distribution in cities and rural areas alike.

Between 2015 and 2022, overdose death rates quadrupled for adults aged 35 – 44, and Black and Indigenous Americans saw the sharpest increases. Emergency rooms logged a 30% jump in suspected opioid overdose visits in 2020, exposing the urgent need for up-to-the-minute data. Automated dashboards now connect pharmacy records, EMS calls, and death certificates – pinpointing hotspots.

CDC surveillance now drives the pace and map of the crisis, but persistent data gaps – especially around overdose causes – still leave the full picture out of focus.